2013
DOI: 10.2174/1568026611212220014
|View full text |Cite
|
Sign up to set email alerts
|

Protein Homeostasis as a Therapeutic Target for Diseases of Protein Conformation

Abstract: Protein misfolding and aggregation are widely implicated in an increasing number of human diseases providing for new therapeutic opportunities targeting protein homeostasis (proteostasis). The cellular response to proteotoxicity is highly regulated by stress signaling pathways, molecular chaperones, transport and clearance machineries that function as a proteostasis network (PN) to protect the stability and functional properties of the proteome. Consequently, the PN is essential at the cellular and organismal … Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
2

Citation Types

1
55
0

Year Published

2013
2013
2018
2018

Publication Types

Select...
5
3

Relationship

0
8

Authors

Journals

citations
Cited by 87 publications
(59 citation statements)
references
References 164 publications
(196 reference statements)
1
55
0
Order By: Relevance
“…The likelihood of developing diseases of protein dysfunction, such as neurodegenerative disorders, is increased upon aging, due in part to the decline of the HSR during the aging process (Ben‐Zvi, Miller, & Morimoto, 2009; Labbadia & Morimoto, 2015). Activators of the HSR have been suggested as possible therapeutic strategies for diseases of aging (Balch, Morimoto, Dillin, & Kelly, 2008; Calamini & Morimoto, 2012; Neef, Turski, & Thiele, 2010; Westerheide & Morimoto, 2005), but many of the small molecules known to modulate HSF1 activity have cytotoxicity and poor bioavailability. Our data suggest that modulating SIR‐2.1 activity may prevent an age‐associated decline in the HSR and may prevent polyglutamine aggregation in a C. elegans Huntington's disease model.…”
Section: Discussionmentioning
confidence: 99%
“…The likelihood of developing diseases of protein dysfunction, such as neurodegenerative disorders, is increased upon aging, due in part to the decline of the HSR during the aging process (Ben‐Zvi, Miller, & Morimoto, 2009; Labbadia & Morimoto, 2015). Activators of the HSR have been suggested as possible therapeutic strategies for diseases of aging (Balch, Morimoto, Dillin, & Kelly, 2008; Calamini & Morimoto, 2012; Neef, Turski, & Thiele, 2010; Westerheide & Morimoto, 2005), but many of the small molecules known to modulate HSF1 activity have cytotoxicity and poor bioavailability. Our data suggest that modulating SIR‐2.1 activity may prevent an age‐associated decline in the HSR and may prevent polyglutamine aggregation in a C. elegans Huntington's disease model.…”
Section: Discussionmentioning
confidence: 99%
“…Stress-inducible phosphorylation of HSF1, or hyperphosphorylation, is one of the most prominent modifications, coinciding with the acquisition of its transactivation capacity (30,(37)(38)(39)(40). However, despite a wealth of studies on the role of single phosphorylation sites (29,30,34,(40)(41)(42), no direct link between hyperphosphorylation and HSF1 activation has been established.Many pathological conditions, such as metabolic disorders, cancers, and neurodegenerative diseases, are associated with either increased or decreased activity of molecular chaperones (43,44). Hence, modulating the heat shock response by altering HSF1 activity has been proposed as a potential therapeutic approach …”
mentioning
confidence: 99%
“…Many pathological conditions, such as metabolic disorders, cancers, and neurodegenerative diseases, are associated with either increased or decreased activity of molecular chaperones (43,44). Hence, modulating the heat shock response by altering HSF1 activity has been proposed as a potential therapeutic approach (44)(45)(46).…”
mentioning
confidence: 99%
See 1 more Smart Citation
“…A better understanding of this process may enable the development of new approaches to treat misfolding and aggregation diseases. Guiding misfolded proteins towards beneficial PQC compartments, or away from potentially detrimental ones may represent the next direction of therapeutic design in the field of protein misfolding disorders (reviewed in [59,62]). Thus, it remains critical to understand the cell biology involved in PQC body formation in order to design appropriate therapeutic approaches for the wide range of misfolding diseases.…”
Section: Discussionmentioning
confidence: 99%